Amwill Health Care Ltd
Incorporated in 2009, Amwill Health Care is in the wholesale trading of pharmaceutical products[1]
- Market Cap ₹ 137 Cr.
- Current Price ₹ 68.4
- High / Low ₹ 105 / 63.0
- Stock P/E 12.8
- Book Value ₹ 34.6
- Dividend Yield 0.00 %
- ROCE 27.6 %
- ROE 24.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 46.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has high debtors of 163 days.
- Working capital days have increased from 79.8 days to 166 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 17 | 26 | 28 | 42 | 37 | |
| 18 | 22 | 24 | 25 | 26 | |
| Operating Profit | -1 | 4 | 4 | 17 | 12 |
| OPM % | -6% | 14% | 15% | 40% | 31% |
| 0 | -0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -1 | 3 | 4 | 17 | 12 |
| Tax % | -3% | 23% | 25% | 25% | 10% |
| -1 | 3 | 3 | 12 | 11 | |
| EPS in Rs | -333.33 | 856.67 | 1,036.67 | 2,500.00 | 5.36 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | -10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 60% |
| TTM: | -14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.05 | 20 |
| Reserves | -1 | 1 | 5 | 17 | 49 |
| 0 | 0 | 0 | 0 | 0 | |
| 9 | 5 | 8 | 2 | 2 | |
| Total Liabilities | 8 | 7 | 12 | 19 | 71 |
| 1 | 0 | 1 | 1 | 1 | |
| CWIP | 0 | 0 | 0 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 7 | 6 | 12 | 18 | 70 | |
| Total Assets | 8 | 7 | 12 | 19 | 71 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0 | 3 | 5 | -3 | 6 | |
| -1 | -0 | -1 | -1 | -46 | |
| 0 | 0 | -0 | -0 | 41 | |
| Net Cash Flow | -1 | 3 | 3 | -4 | 1 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 93 | 12 | 16 | 114 | 163 |
| Inventory Days | 66 | ||||
| Days Payable | 39 | ||||
| Cash Conversion Cycle | 93 | 12 | 16 | 141 | 163 |
| Working Capital Days | -42 | -23 | -38 | 111 | 166 |
| ROCE % | 1,069% | 133% | 153% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Newspaper Publication- Notice of 08th Annual General Meeting of Amwill Helath Care Limited , evoting Information.
-
Reg. 34 (1) Annual Report.
18 Jul - Notice of 8th AGM on Aug 14, 2025, including financials, director re-appointments, and e-voting details.
- Notice Of 08Th Annual General Meeting And Annual Report For FY 2024-25 18 Jul
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Jul - Newspaper Advertisments- 08th Annual General Meeting through Video Conferencing/ other Audio- Visual Means ("VC/OAVM") facility.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jul - Compliance certificate confirming no dematerialisation/rematerialisation requests for Q1 FY2025-26.
Business Overview:[1][2]
a) AHL focuses on Dermatology, Trichology, and Cosmetology.
b) It creates advanced skincare solutions using dermatological actives, natural ingredients, and specialized techniques.
c) Operates as a dermal-cosmetic developer, collaborating with contract manufacturers, distributors, and third-party developers.
d) Follows an asset-light model, outsourcing testing, manufacturing, and distribution.